Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · August 04, 2015

Risk of Bleeding and Thromboembolic Events in Newly Treated Nonvalvular Atrial Fibrillation

Circulation

 

Additional Info

Circulation
Comparison of the Short-Term Risk of Bleeding and Arterial Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Newly Treated With Dabigatran or Rivaroxaban Versus Vitamin K Antagonists: A French Nationwide Propensity-Matched Cohort Study
Circulation 2015 Jul 21;[EPub Ahead of Print], G Maura, PO Blotière, K Bouillon, C Billionnet, P Ricordeau, F Alla, M Zureik

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading